Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States
Emergent BioSolutions Inc. (EBS)
Last emergent biosolutions inc. earnings: 4/30 04:08 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.emergentbiosolutions.com
Company Research
Source: GlobeNewswire
Emergent’s Canton facility will manufacture drug substance and obtains exclusive distribution rights GAITHERSBURG, Md. and GENEVA, April 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has entered into an agreement with Substipharm Biologics valued at approximately $34.5 million to support drug substance manufacturing for its Japanese Encephalitis (JE) vaccine, licensed internationally under the brand name IMOJEV® at Emergent’s Canton, Massachusetts facility, and for Emergent to serve as the exclusive distributor of the vaccine to the U.S. government, following potential U.S. Food & Drug Administration (FDA) regulatory endeavors. Emergent Canton is a BSL-2, multi-product commercial facility that provides viral drug substance manufacturing. Following an inspection in February 2026, the FDA listed “No Action Indicated” status classification for the Canton manufacturing facility, reflecting Emergent’s commitment to ensuring continued compliance
Show less
Read more
Impact Snapshot
Event Time:
EBS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EBS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EBS alerts
High impacting Emergent BioSolutions Inc. news events
Weekly update
A roundup of the hottest topics
EBS
News
- Blue Jays player Davis Schneider says naloxone can save lives after brother's fatal 2020 overdose [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Davis Schneider's brother died of an overdose. The Blue Jay says naloxone can save others [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142GlobeNewswire
- Emergent BioSolutions Partners with Professional Baseball Player Davis Schneider to Raise Awareness of NARCAN® Nasal Spray Among Canadians and Help Save LivesGlobeNewswire
- Emergent Biosolutions (EBS) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "sell (d+)" to "sell (d)".MarketBeat
EBS
Earnings
- 10/29/25 - Beat
EBS
Sec Filings
- 4/29/26 - Form SCHEDULE
- 4/28/26 - Form DEFA14A
- 4/27/26 - Form DEFA14A
- EBS's page on the SEC website